NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Cybersickness Prevention and Mitigation in Virtual Reality for Healthy Volunteers

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

001975-HG

Sponsoring Institute

National Human Genome Research Institute (NHGRI)

Recruitment Detail

Type: Recruitment has not started
Gender: Male & Female
Min Age: 18 Years
Max Age: 60 Years

Referral Letter Required

No

Population Exclusion(s)

Adults who are or may become unable to consent;
Fetuses;
Children;
Neonates;
Pregnant Women

Keywords

Healthy Volunteers;
Virtual Reality;
cybersickness

Recruitment Keyword(s)

None

Condition(s)

Healthy Volunteers;
virtual reality

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Behavioral: Motion Reset
Behavioral: Placebo

Supporting Site

National Human Genome Research Institute

Background:

People use virtual reality (VR) technology to play games, socialize, work, or receive medical care. Some people have "cybersickness" after using VR. Cybersickness is similar to motion sickness. Symptoms include eye strain, nausea, dizziness, or headache. The symptoms are usually mild and go away after the person stops using VR. New software called Motion Reset is being designed to reduce symptoms of cybersickness during VR use.

Objective:

To see if Motion Reset software can reduce cybersickness in people using VR.

Eligibility:

Healthy adults aged 18 to 60 years.

Design:

Participants will have 1 clinic visit that will last about 1 hour. They will answer questions about how they are feeling. They will learn how to use the VR headset and the handheld game controllers.

The study will be broken into 2 parts. For the first part, participants will be assigned to 1 of 3 groups:

Group 1 will participate in a VR experience designed to prevent cybersickness. They will view screens and move around while they press buttons on a controller.

Group 2 will participate in a VR experience that is not designed to prevent cybersickness. They will view screens and move around while they press buttons on a controller.

Group 3 will have no VR experience.

Participants will complete 2 questionnaires about their experiences in the first part of the study.

For the second part, all participants will spend up to 20 minutes playing a commercial VR game called Jurassic World Aftermath. Every few minutes, they will be asked if they are experiencing discomfort.

After playing the game, participants will complete 12 questionnaires about their experience.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

-Provision of signed and dated informed consent form

-Stated willingness to comply with all study procedures and availability for the duration of the study

-Aged 18-60

-Ability to read, speak, and write in English

-Normal or corrected-to-normal hearing

-Normal vision or corrected-to-normal without use of glasses. Contact lenses for corrective purposes are acceptable.

Ability to read, speak and write in English is a requirement because the VR-based study materials and assessment are only available in English and several of the key questionnaires for the study are not validated in other languages.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

-Reporting motion sickness propensity of 0 or 10 on a 0-10 scale where 0 =never experience motion sickness and 10 = experience motion sickness very frequently (self-assessed by participants).

-Reporting a history of photo-sensitive seizure disorders, vestibular disorders and/or other conditions that may make participants prone to nausea, dizziness, vertigo, ataxia, or incoordination.

-Known pregnancy

-Reporting current use of medication or supplements that inhibit nausea, e.g., Zofran/ondansetron, Phenergan/promethazine


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Susan Persky, Ph.D.
National Human Genome Research Institute (NHGRI)
National Institutes of Health
Building 31
Room B1B54D
31 Center Drive
Bethesda, Maryland 20892
(301) 451-1268
perskys@mail.nih.gov

Susan Persky, Ph.D.
National Human Genome Research Institute (NHGRI)
National Institutes of Health
Building 31
Room B1B54D
31 Center Drive
Bethesda, Maryland 20892
(301) 451-1268
NihVRStudy@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT06552754

--Back to Top--